The US Senate has come together to pass a bill that aims to prevent pharma companies from filing multiple patents around biologic drugs as a way to delay biosimilar competitors.
The Federal Trade Commission in the US is planning to sue the owners of the three largest pharmacy benefits managers (PBMs) for anti-competitive behaviour, on the heels of its damning repor
A long-awaited report from the US Federal Trade Commission (FTC) on pharmacy benefit managers (PBMs) is out – and will make uncomfortable reading for the pharma supply chain middlemen.
A Connecticut federal judge has sided with the US Department of Health and Human Services (HHS) in Boehringer Ingelheim's challenge to Medicare’s drug price negotiation programme, rejecting
Shares in Teva Pharmaceutical have dipped sharply after reports that the Federal Trade Commission (FTC) has opened an investigation into the company focusing on improperly listed patents in
Novo Nordisk’ chief executive Lars Fruergaard Jørgensen has agreed to appear at a Senate hearing later this year to defend the pricing of the group’s semaglutide-based therapies for diabete